Recursion Pharmaceuticals (RXRX) Competitors $8.34 +0.68 (+8.88%) Closing price 04:00 PM EasternExtended Trading$8.19 -0.15 (-1.82%) As of 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends RXRX vs. RDY, SRPT, PCVX, QGEN, ROIV, ASND, RVMD, LEGN, BPMC, and AXSMShould you be buying Recursion Pharmaceuticals stock or one of its competitors? The main competitors of Recursion Pharmaceuticals include Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Vaxcyte (PCVX), Qiagen (QGEN), Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Revolution Medicines (RVMD), Legend Biotech (LEGN), Blueprint Medicines (BPMC), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry. Recursion Pharmaceuticals vs. Dr. Reddy's Laboratories Sarepta Therapeutics Vaxcyte Qiagen Roivant Sciences Ascendis Pharma A/S Revolution Medicines Legend Biotech Blueprint Medicines Axsome Therapeutics Recursion Pharmaceuticals (NASDAQ:RXRX) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, community ranking, earnings and profitability. Does the MarketBeat Community prefer RXRX or RDY? Dr. Reddy's Laboratories received 291 more outperform votes than Recursion Pharmaceuticals when rated by MarketBeat users. Likewise, 59.33% of users gave Dr. Reddy's Laboratories an outperform vote while only 57.69% of users gave Recursion Pharmaceuticals an outperform vote. CompanyUnderperformOutperformRecursion PharmaceuticalsOutperform Votes3057.69% Underperform Votes2242.31% Dr. Reddy's LaboratoriesOutperform Votes32159.33% Underperform Votes22040.67% Which has higher valuation & earnings, RXRX or RDY? Dr. Reddy's Laboratories has higher revenue and earnings than Recursion Pharmaceuticals. Recursion Pharmaceuticals is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRecursion Pharmaceuticals$44.58M68.53-$328.07M-$1.53-5.11Dr. Reddy's Laboratories$3.35B3.43$668M$0.6321.93 Do analysts prefer RXRX or RDY? Recursion Pharmaceuticals presently has a consensus price target of $8.75, indicating a potential upside of 11.91%. Dr. Reddy's Laboratories has a consensus price target of $17.00, indicating a potential upside of 23.41%. Given Dr. Reddy's Laboratories' higher probable upside, analysts plainly believe Dr. Reddy's Laboratories is more favorable than Recursion Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Recursion Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Dr. Reddy's Laboratories 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media prefer RXRX or RDY? In the previous week, Recursion Pharmaceuticals and Recursion Pharmaceuticals both had 12 articles in the media. Recursion Pharmaceuticals' average media sentiment score of 0.88 beat Dr. Reddy's Laboratories' score of 0.35 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Recursion Pharmaceuticals 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dr. Reddy's Laboratories 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals believe in RXRX or RDY? 89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 15.8% of Recursion Pharmaceuticals shares are owned by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more risk & volatility, RXRX or RDY? Recursion Pharmaceuticals has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500. Is RXRX or RDY more profitable? Dr. Reddy's Laboratories has a net margin of 17.25% compared to Recursion Pharmaceuticals' net margin of -579.52%. Dr. Reddy's Laboratories' return on equity of 17.87% beat Recursion Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Recursion Pharmaceuticals-579.52% -76.56% -55.68% Dr. Reddy's Laboratories 17.25%17.87%12.32% SummaryDr. Reddy's Laboratories beats Recursion Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Get Recursion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RXRX vs. The Competition Export to ExcelMetricRecursion PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.06B$3.07B$5.68B$9.00BDividend YieldN/A1.79%5.32%4.00%P/E Ratio-5.1145.8687.3919.27Price / Sales68.53318.721,048.5074.40Price / CashN/A192.7646.0938.87Price / Book3.953.935.054.98Net Income-$328.07M-$40.60M$113.45M$222.68M7 Day Performance-1.28%-6.35%-1.94%-1.16%1 Month Performance13.65%-2.71%2.98%2.29%1 Year Performance-28.53%-10.55%21.12%17.27% Recursion Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RXRXRecursion Pharmaceuticals1.628 of 5 stars$8.34+8.9%$8.75+4.9%-24.1%$3.26B$44.58M-5.45400Gap DownRDYDr. Reddy's Laboratories2.0849 of 5 stars$13.80-0.7%$17.00+23.2%-6.8%$11.52B$3.35B21.9727,048Short Interest ↑Analyst RevisionSRPTSarepta Therapeutics4.6757 of 5 stars$113.57+1.6%$178.71+57.4%-13.5%$10.83B$1.24B90.681,314Analyst ForecastPCVXVaxcyte2.5806 of 5 stars$86.19-1.4%$145.71+69.1%+13.8%$10.76BN/A-18.77160Analyst ForecastQGENQiagen4.3624 of 5 stars$40.30-2.5%$48.78+21.1%-9.0%$8.96B$1.98B112.455,967Earnings ReportAnalyst RevisionROIVRoivant Sciences3.6788 of 5 stars$10.92+0.2%$17.93+64.3%-3.0%$7.97B$124.79M1.94860Earnings ReportAnalyst ForecastASNDAscendis Pharma A/S3.0482 of 5 stars$120.89+0.0%$191.57+58.5%-15.7%$7.34B$288.08M-14.96640Earnings ReportAnalyst ForecastNews CoverageRVMDRevolution Medicines4.5176 of 5 stars$42.27+0.2%$66.25+56.7%+36.2%$7.13B$11.58M-11.80250Positive NewsLEGNLegend Biotech2.5696 of 5 stars$35.87+1.4%$79.50+121.7%-43.2%$6.56B$285.14M-37.831,800BPMCBlueprint Medicines2.1135 of 5 stars$102.90-2.0%$123.72+20.2%+32.7%$6.53B$434.42M-48.73640Short Interest ↓Analyst RevisionGap DownAXSMAxsome Therapeutics4.4497 of 5 stars$129.85+22.8%$134.00+3.2%+36.4%$6.32B$270.60M-19.97380Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageHigh Trading Volume Related Companies and Tools Related Companies Dr. Reddy's Laboratories Competitors Sarepta Therapeutics Competitors Vaxcyte Competitors Qiagen Competitors Roivant Sciences Competitors Ascendis Pharma A/S Competitors Revolution Medicines Competitors Legend Biotech Competitors Blueprint Medicines Competitors Axsome Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RXRX) was last updated on 2/12/2025 by MarketBeat.com Staff From Our Partners$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredNvidia > DeepSeekEveryone's getting it all wrong … Sure, DeepSeek's reveal caused AI stocks to tumble … But, in the long ...Weiss Ratings | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | Sponsored New Options "Trading GPS" = 91% Win-RateThink of it as GPS navigation for the options market... Even traders who previously found options "too comp...Eagle Publishing | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | SponsoredMarket down? Do this now.The Trump administration's new tariffs have already begun to shake the economy. The impact is real, and the cl...Colonial Metals | SponsoredTrump Policies Are Going to Light a Fire Under GoldHow You Can Profit from Trump's Bold Moves in 2025 Donald Trump’s bold policies are creating unprecedented ...Golden Portfolio | SponsoredMust-See: Trump’s Shocking AI AnnouncementIf you have any investments in AI stocks or are interested in AI… Please take a moment to review the detail...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recursion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Recursion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.